vs
Side-by-side financial comparison of Avidbank Holdings, Inc. (AVBH) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
Avidbank Holdings, Inc. is the larger business by last-quarter revenue ($28.0M vs $18.6M, roughly 1.5× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs 32.3%, a 33.5% gap on every dollar of revenue.
Avidbank Holdings, Inc. is a U.S.-based financial holding company operating through its subsidiary AvidBank. It offers commercial banking products and services primarily to small and medium-sized enterprises, business owners, and high-net-worth individuals across California, including commercial loans, deposit accounts, cash management, and customized financing solutions for sectors like manufacturing, technology, real estate and professional services.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
AVBH vs SCYX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $28.0M | $18.6M |
| Net Profit | $9.0M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | — | 56.3% |
| Net Margin | 32.3% | 65.7% |
| Revenue YoY | — | 1808.5% |
| Net Profit YoY | 65.9% | 376.5% |
| EPS (diluted) | $0.84 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $28.0M | — | ||
| Q4 25 | $26.8M | $18.6M | ||
| Q3 25 | $48.0K | $334.0K | ||
| Q2 25 | $21.8M | $1.4M | ||
| Q1 25 | — | $257.0K | ||
| Q4 24 | — | $977.0K | ||
| Q3 24 | — | $660.0K | ||
| Q2 24 | — | $736.0K |
| Q1 26 | $9.0M | — | ||
| Q4 25 | $6.9M | $12.3M | ||
| Q3 25 | $-37.7M | $-8.6M | ||
| Q2 25 | $5.8M | $-6.9M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-2.8M | ||
| Q2 24 | — | $-14.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 56.3% | ||
| Q3 25 | -110491.7% | -2516.5% | ||
| Q2 25 | 38.0% | -701.0% | ||
| Q1 25 | — | -3350.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -1563.6% | ||
| Q2 24 | — | -1255.0% |
| Q1 26 | 32.3% | — | ||
| Q4 25 | 25.9% | 65.7% | ||
| Q3 25 | -78614.6% | -2572.2% | ||
| Q2 25 | 26.6% | -504.8% | ||
| Q1 25 | — | -2097.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -425.5% | ||
| Q2 24 | — | -1964.4% |
| Q1 26 | $0.84 | — | ||
| Q4 25 | $0.65 | $0.25 | ||
| Q3 25 | $-4.12 | $-0.17 | ||
| Q2 25 | $0.75 | $-0.14 | ||
| Q1 25 | — | $-0.11 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.06 | ||
| Q2 24 | — | $-0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $40.0M |
| Total DebtLower is stronger | $55.0M | — |
| Stockholders' EquityBook value | $287.2M | $49.4M |
| Total Assets | $2.5B | $59.0M |
| Debt / EquityLower = less leverage | 0.19× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $40.0M | ||
| Q3 25 | — | $37.9M | ||
| Q2 25 | — | $44.8M | ||
| Q1 25 | — | $40.6M | ||
| Q4 24 | — | $59.3M | ||
| Q3 24 | — | $68.8M | ||
| Q2 24 | — | $73.0M |
| Q1 26 | $55.0M | — | ||
| Q4 25 | $60.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $287.2M | — | ||
| Q4 25 | $278.4M | $49.4M | ||
| Q3 25 | $273.1M | $36.4M | ||
| Q2 25 | $204.4M | $44.5M | ||
| Q1 25 | — | $50.5M | ||
| Q4 24 | — | $55.1M | ||
| Q3 24 | — | $58.5M | ||
| Q2 24 | — | $60.4M |
| Q1 26 | $2.5B | — | ||
| Q4 25 | $2.5B | $59.0M | ||
| Q3 25 | $2.4B | $51.1M | ||
| Q2 25 | $2.4B | $60.7M | ||
| Q1 25 | — | $67.9M | ||
| Q4 24 | — | $90.6M | ||
| Q3 24 | — | $99.0M | ||
| Q2 24 | — | $107.8M |
| Q1 26 | 0.19× | — | ||
| Q4 25 | 0.22× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $18.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $18.4M | ||
| Q3 25 | $12.4M | $-8.7M | ||
| Q2 25 | $10.7M | $-7.5M | ||
| Q1 25 | — | $-7.5M | ||
| Q4 24 | — | $-24.0M | ||
| Q3 24 | — | $765.0K | ||
| Q2 24 | — | $-10.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $12.4M | — | ||
| Q2 25 | $10.6M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 25783.3% | — | ||
| Q2 25 | 48.6% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 72.9% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.84× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVBH
| Net Interest Income | $26.5M | 95% |
| Noninterest Income | $1.5M | 5% |
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
